The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy
Diabetes/Metabolism Research and Reviews · 2023
DOI: 10.1002/dmrr.3694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2023. Verfasst von Chiara Grasselli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Receptors, Interleukin-8B, Receptors, Interleukin-8A, Podocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero dello Sviluppo Economico, Ladarixin as new Juvenile Diabetes Inhibitory Agent, Fondo crescita sostenibile-Proposal.
Abstract (Originalsprache)
Aims
Diabetic nephropathy is a major consequence of inflammation developing in type 1 diabetes, with interleukin‐8 (IL‐8)‐CXCR1/2 axis playing a key role in kidney disease progression. In this study, we investigated the therapeutic potential of a CXCR1/2 non‐competitive allosteric antagonist (Ladarixin) in preventing high glucose‐mediated injury in human podocytes and epithelial cells differentiated from renal stem/progenitor cells (RSC) cultured as nephrospheres. Materials and Methods We used human RSCs cultured as nephrospheres through a sphere‐forming functional assay to investigate hyperglycemia‐mediated effects on IL‐8 signalling in human podocytes and tubular epithelial cells.
Results
High glucose impairs RSC self‐renewal, induces an increase in IL‐8 transcript expression and protein secretion and induces DNA damage in RSC‐differentiated podocytes, while exerting no effect on RSC‐differentiated epithelial cells. Accordingly, the supernatant from epithelial cells or podocytes cultured in high glucose was able to differentially activate leucocyte‐mediated secretion of pro‐inflammatory cytokines, suggesting that the crosstalk between immune and non‐immune cells may be involved in disease progression in vivo.
Conclusions
Treatment with Ladarixin during RSC differentiation prevented high glucose‐mediated effects on podocytes and modulated either podocyte or epithelial cell‐dependent leucocyte secretion of pro‐inflammatory cytokines, suggesting CXCR1/2 antagonists as possible pharmacological approaches for the treatment of diabetic nephropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
- Pathology Department, IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy.
- Dompé Farmaceutici S.p.A., Naples, Italy.
- Research and Development, Dompé Farmaceutici S.p.A., Milano, Italy.
- Dompé Farmaceutici S.p.A., L'Aquila, Italy.
ORCID-Profile: Michele Francesco Di Tolla, Francesca Rocchio, Pier Adelchi Ruffini, Roberto Perego
Förderung
- Ministero dello Sviluppo Economico
- Ladarixin as new Juvenile Diabetes Inhibitory Agent
- Fondo crescita sostenibile-Proposal
Zitieren
APA
Grasselli, C., Bombelli, S., D'Esposito, V., Di Tolla, M. F., L'Imperio, V., Rocchio, F., Miscione, M. S., Formisano, P., Pagni, F., Novelli, R., Ruffini, P. A., Aramini, A., Allegretti, M., Perego, R., & De Filippis, L. (2023). The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3694
Vancouver
Grasselli C, Bombelli S, D'Esposito V, Di Tolla MF, L'Imperio V, Rocchio F, et al. The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy. Diabetes/Metabolism Research and Reviews. 2023. doi:10.1002/dmrr.3694
BibTeX
@article{Grasselli2023,
author = {Grasselli, Chiara and Bombelli, Silvia and D'Esposito, Vittoria and Di Tolla, Michele Francesco and L'Imperio, Vincenzo and Rocchio, Francesca and Miscione, Martina Sara and Formisano, Pietro and Pagni, Fabio and Novelli, Rubina and Ruffini, Pier Adelchi and Aramini, Andrea and Allegretti, Marcello and Perego, Roberto and De Filippis, Lidia},
title = {The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2023},
doi = {10.1002/dmrr.3694}
}
EUVIMED